HilleVax(US:HLVX)2024-11-07 13:05Financial Performance - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $189.3 million, down from $303.5 million as of December 31, 2023[2] - Research and development expenses for Q3 2024 were $20.2 million, a decrease of 26.5% compared to $27.3 million in Q3 2023[2] - General and administrative expenses for Q3 2024 were $6.2 million, down from $6.6 million in Q3 2023, reflecting a decrease of 6.1%[2] - The net loss for Q3 2024 was $25.8 million, compared to a net loss of $31.8 million in Q3 2023, representing a reduction of 18.5%[2] - The company reported total operating expenses of $26.4 million for Q3 2024, down from $33.9 million in Q3 2023, a decrease of 22.1%[6] - Total assets as of September 30, 2024, were $220.6 million, significantly lower than $344.4 million as of December 31, 2023[7] - Total liabilities decreased to $36.3 million as of September 30, 2024, from $78.9 million at the end of 2023[7] Strategic Development - The company is exploring continued development of its norovirus vaccine candidates and other strategic alternatives[1] - HilleVax's vaccine candidates aim to address the global burden of norovirus, which causes approximately 700 million cases of acute gastroenteritis annually[3] - The company has indicated potential workforce reductions and related strategic activities as part of its future plans[4]